WE.SPEED.
Neuroscience clinical trials thrive on a diverse range of factors such as novel target identification methods, comprehensive AI integration, real-world data analysis, ongoing advancements in cell and gene therapies, and cutting-edge imaging technology.
Recent drug approvals validate the effectiveness of addressing the significant challenge of influencing cognitive decline through the latest advancements.
In the unique realm of early-stage clinical trials, the convergence of emerging targets, technological breakthroughs, and newfound knowledge in CNS pathophysiology necessitates a delicate balance of flexibility, speed, and quality, where the crucial "go or no-go" decision for advancing a new therapy must be made rapidly, supported by dependable data, amidst competitive and cost-effective pressures.
ARENSIA Research Clinics, strategically situated in the USA, Romania, Bulgaria, Moldova, Georgia, Ukraine, and Morocco, are purpose-built facilities that facilitate rapid patient enrollment and prioritize safety and data quality, allowing for groundbreaking exploration of new targets in various neuro-psychiatric indications. Equipped with cutting-edge Phase I infrastructure, these clinics are fully dedicated to conducting exploratory clinical trials in patients.
ARENSIA Clinics provide unparalleled access to vast patient populations encompassing mood disorders (major depressive disorder, generalized anxiety disorder, post-traumatic stress disorder), demyelinating disorders, movement disorders, dementias, pain, epilepsies, sleep disorders, and even rare and distinctive populations.
Equipped with a dedicated team of full-time neurology experts including physicians, nurses, technicians, and project coordinators, ARENSIA possesses extensive proficiency in executing highly intricate Phase I/First-in-Patient and Phase II protocols featuring adaptive designs, intensive assessments, and advanced imaging procedures that surpass standard practices.
Through a robust research alliance, we have established a formidable collaboration with clinical trial participants, leveraging new technology to monitor compliance, activity levels, daily functioning, and facilitating the seamless collection of patient-reported outcomes on an ongoing basis.
With regulatory approval timelines as short as 15 days in Moldova, 30-45 days in Georgia, Ukraine, Morocco, and the USA, and 60-90 days in Romania and Bulgaria (EU countries), ARENSIA clinics have emerged as the global leaders in achieving the first patient in milestone, offering unparalleled speed in clinical trial initiation.
The following case studies exemplify the unparalleled effectiveness of ARENSIA's model. We take pride in providing patients with access to the most innovative therapies early in the drug development process while enabling sponsors to fast-track their neuroscience pipelines with remarkable speed.
We are thrilled to collaborate with visionary research companies to drive forward the development of groundbreaking neuro-psychiatric therapies.
For more information, please do not hesitate to contact us at info@arensia-em.com
11.09.2023